By G HossainPosted on January 13, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 Post navigation JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent CliffJ&J To Add 500 Jobs at New Plant, Doubling Down on North Carolina